Intensified postoperative treatment in cases of herpetic recurrence and in instances of graft rejection
| Drug | Daily dose | Duration | |
|---|---|---|---|
| *Maximum dose; modifications necessitated by differences in renal function and body weight (bw) were as recommended by the manufacturer. | |||
| Intensified postoperative treatment in cases of herpetic recurrence (based on clinical judgement, irrespective of group affiliation) | |||
| I Systemic treatment | |||
| Keratouveitis | Aciclovir | 3 × 10 mg/kg bw* IV | 7–10 days |
| 3 × 800 mg* by mouth | 2–4 weeks | ||
| Endotheliitis | Aciclovir | 5 × 800 mg* by mouth | 2 weeks |
| 3 × 800 mg* by mouth | 2 weeks | ||
| Stromal keratitis | Aciclovir | 3 × 800 mg* by mouth | 2 weeks |
| Subsequent prophylaxis | Aciclovir | 3 × 400 mg* by mouth | 4–12 months |
| II Topical treatment | |||
| Epithelial keratitis | Aciclovir | 5 × 3% ointment | 10–30 days |
| Herpetic recurrence | Prednisolone | 5 × 1% eyedrops | whole episode |
| Accompanying uveitis | Cycloplegics | According to clinical symptoms and signs | |
| Intensified postoperative treatment in instances of graft rejection (aciclovir only in cases of herpetic stromal keratitis (group 1)) | |||
| I Systemic treatment | Prednisolone | 1–2 mg/kg bw* | 3 days; subsequent dose tapering |
| Aciclovir | 3 × 400 mg* by mouth | during high dose local steroid therapy | |
| II Topical treatment | Prednisolone acetate | 2.5% eyedrops | every 30–60 minutes; subsequent dose tapering |
| Cycloplegics | according to clinical symptoms and signs | ||